Systemic anti-cancer therapy: management options for people with non-squamous (adenocarcinoma, large cell undifferentiated) carcinoma and non-small-cell carcinoma (non-otherwise specified) – April 2020 update

- **Platinum doublet chemotherapy**
  - (when using Pemetrexed+Cisplatin as first-line treatment see TA181)

- **Crizotinib (TA406)**
  - **Ceritinib (TA395)**

- **Atezolizumab (no PD-L1 expression needed) (TA520) or Nivolumab (if PD-L1 >1%) (TA484) or Pembrolizumab (TA557)**

- **Docetaxel +/- Nintedanib (TA347)**

- **Pemetrexed maintenance (TA402 or TA190)**

- **T790M positive?**
  - **Y**
    - **Osimertinib (TA416)**
  - **N**
    - **Atezolizumab**
      - **bevacizumab, carboplatin and paclitaxel* (TA584)**
      - **Pemetrexed+ bevacizumab, carboplatin and paclitaxel* (TA584)**
  - **Crizotinib (TA529)**
  - **Pembrolizumab + pemetrexed and platinum chemotherapy (TA557)**

- **Disease progression**
  - **Cancer Drugs Fund**

**New addition**

- **Pembrolizumab**

*This combination/some of these combinations of drugs do not have a UK marketing authorisation for 1 or more indications.*